Molecules, Vol. 24, Pages 1924: Reconsidering the Role of Cyclooxygenase Inhibition in the Chemotherapeutic Value of NO-Releasing Aspirins for Lung Cancer
Molecules, Vol. 24, Pages 1924: Reconsidering the Role of Cyclooxygenase Inhibition in the Chemotherapeutic Value of NO-Releasing Aspirins for Lung Cancer
Molecules doi: 10.3390/molecules24101924
Authors:
Antonia Martin-Martin
Andrés Rivera-Dictter
Matías Muñoz-Uribe
Freddy López-Contreras
Jorge Pérez-Laines
Alfredo Molina-Berríos
Rodrigo López-Muñoz
Nitric oxide-releasing aspirins (NO-aspirins) are aspirin derivatives that are safer than the parent drug in the gastrointestinal context and have shown superior cytotoxic effects in several cancer models. Despite the rationale for their design, the influence of nitric oxide (NO•) on the effects of NO-aspirins has been queried. Moreover, different isomers exhibit varying antitumor activity, apparently related to their ability to release NO•. Here, we investigated the effects and mode of action of NO-aspirins in non-small-cell lung cancer (NSCLC) cells, comparing two isomers, NCX4016 and NCX4040 (-meta and -para isomers, respectively). NCX4040 was more potent in decreasing NSCLC cell viability and migration and exhibited significant synergistic effects in combination with erlotinib (an epidermal growth factor receptor inhibitor) in erlotinib-resistant cells. We also studied the relationship among the effects of NO-aspirins, NO• release, and PGE2 levels. NCX4040 released more NO• and significantly decreased PGE2 synthesis relative to NCX4016; however, N...
Source: Molecules - Category: Chemistry Authors: Antonia Martin-Martin Andr és Rivera-Dictter Mat ías Muñoz-Uribe Freddy L ópez-Contreras Jorge P érez-Laines Alfredo Molina-Berr íos Rodrigo L ópez-Muñoz Tags: Article Source Type: research
More News: Aspirin | Cancer | Cancer & Oncology | Chemistry | Gastroenterology | Lung Cancer | Non-Small Cell Lung Cancer | Tarceva